Dr Ring talks to ecancertv at SABCS 2013 about the 'Add-aspirin trial'.
This is a phase III double-blind placebo-controlled randomized trial assessing the addition of aspirin after standard primary therapy in breast cancer and other early stage common solid tumours.
The primary outcome will be disease-free survival. Secondary endpoints include overall survival, toxicity, cardiac morbidity and assessment of overall healthcare benefits.
Translational work will investigate mechanisms of action and biomarkers for toxicity and treatment efficacy (including PIK3CA mutation status and COX-2 expression).
Approximately 3100 patients will be needed to test for a 4% improvement in disease free survival associated with aspirin use.